ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Questions about BMS-Celgene integration plans? Obviously. Answers? Not so much
April 29, 2019Now that shareholders have voted for the deal, Bristol-Myers Squibb faces some serious pressure to prove its Celgene buyout will actually pay off. So it's no wonder analysts are demanding to know... -
BMS-Celgene merger chances improve with backing from proxy advisers
April 02, 2019When it comes to Bristol-Myers Squibb’s Celgene merger, two influential proxy advisory firms have spoken—and they’re in favor of the mammoth tie-up. -
The BMS-Celgene merger’s Achilles heel? An earlier-than-expected Revlimid patent loss
January 08, 2019Executives from Bristol-Myers Squibb and Celgene were just a few minutes into a Q&A with investors about their newly announced $74 billion merger when longtime biotech analyst Tim Anderson raised a troubling question.
Pharma Sources Insight January 2025
